<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01372995</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00049610</org_study_id>
    <nct_id>NCT01372995</nct_id>
  </id_info>
  <brief_title>Vitamin D in Ventilated ICU Patients</brief_title>
  <acronym>R21 HL-110044</acronym>
  <official_title>High-Dose Vitamin D and Antimicrobial Peptide Expression in Lung Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The increasing rate of hospital-acquired infection and antibiotic resistance are major causes
      of prolonged ICU stay and death in hospitalized patients. The enormous impact of ICU-related
      infection demands the need for cost-effective therapies that can be rapidly implemented to
      improve patient immune response to control infection. Unfortunately, little high-quality
      comparative effectiveness research has been performed on micronutrient treatment regimens as
      methods to decrease hospital-acquired infection in critically ill patients. Critically ill
      medical and surgical patients have an extremely high prevalence of vitamin D insufficiency.

      We will perform a rigorous, double-blind, randomized, controlled, pilot clinical trial in
      ventilator-dependent ICU patients to test the clinical/metabolic safety and efficacy of two
      doses of oral high-dose vitamin D3 therapy versus standard therapy (no supplemental vitamin
      D). The primary endpoint is to test whether high-dose regimens [either 50,000 or 100,000
      international units (IU) of enteral vitamin D3 given daily for 5 consecutive days (total dose
      = 250,000 or 500,000 IU, respectively) increase plasma 25(OH)D concentrations into a
      desirable range (&gt; 30 ng/mL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. We will evaluate, over 12 weeks, the safety and efficacy of two high-dose vitamin D3
           regimens in severely ill ICU patients. Vitamin D or placebo ( depending on study arm)
           will be given sequentially in divided doses for 5 days

        2. We will explore whether these vitamin D regimens are capable of increasing the
           production of key antimicrobial peptides LL-37 and hBD-2 ( substances produced by our
           bodies to fight infections), in both the blood and in lung.

        3. We will determine whether a higher vitamin D level in the blood is associated with a
           decrease in hospital infection rates and other complications in high-risk ICU patients
           with respiratory failure.

      Study Design:

      Enrollment goal is 36 patients. Once consent is obtained subjects will be randomly assigned
      to one of three study groups. Each group consists of 12 patients with enteral access ; a
      placebo arm, an arm where subjects receive 50,000 IU of Vitamin D for 5 days, and a third arm
      where subjects receive 100,000 IU of Vitamin D for 5 days.

      Methods: Baseline blood samples (25-hydroxyvitamin D, vitamin D binding protein, ionized
      calcium, LL-37,and hBD-2) will be taken on study day 7,14,21,28,84 days. On study day 1 and
      8, LL-37, hBD-2, cathelicidin from BAL fluid will also be analyzed. Patients will be given
      either placebo, Vitamin D3 50,000 IU x 5 days (total 250,000 IU) or Vitamin D3 100,000 IU x 5
      days (total 500,000 IU) with an intention to treat model. Baseline data on the patients
      including demographic, laboratory, documented infections, severity illness score (APACHE II)
      and organ dysfunction score (SOFA) will be collected. ELISA assay on the serum and BAL will
      be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the baseline measurement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the Day 7 measurement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the Day 14 measurement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Day 21</measure>
    <time_frame>Day 21</time_frame>
    <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the Day 21 measurement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the Day 28 measurement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Day 84</measure>
    <time_frame>Day 84</time_frame>
    <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the Day 84 measurement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma LL-37 Levels</measure>
    <time_frame>Baseline, Day 7, Day 14</time_frame>
    <description>Plasma LL-37 was measured at Baseline, Day 7 and Day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Time on Ventilator</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of days spent on mechanical ventilation was collected for all study participants and the average number of days for each study arm is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Time in Intensive Care Unit (ICU)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of days spent in the intensive care unit (ICU) was collected for each participant and the average number of days for each study arm is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Time in Hospital</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of days that each participant spent in the hospital was collected and the average number of days for each study arm is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sequential Organ Failure Assessment (SOFA) Score</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>Change in Sequential Organ Failure Assessment (SOFA) score between Baseline and Day 7. The Sequential Organ Failure Assessment (SOFA) score is a mortality prediction score that is based on the degree of dysfunction of 6 organ systems (respiratory, nervous, cardiovascular, liver, coagulation, and kidneys). A score ranges from 0-24. 0 (normal) to 4 (high degree of dysfunction) is given for each organ system, with a higher score indicating greater severity. A score of 0-6 is associated with a mortality rate of less than 10% while a score between 16 and 24 is associated with a greater than 90% mortality rate. Scores decreasing between the Baseline and Day 7 measurements are represented as negative values for the change in SOFA score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospital Acquired Infections</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of study participants who had a hospital acquired infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospital Mortality Cases</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of study participants who died while in the hospital was collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 84 Mortality</measure>
    <time_frame>Day 84</time_frame>
    <description>The number of participants who died prior to the end of the study (Day 84) was collected.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Enteral vitamin D3 50,000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An arm where subjects receive 50,000 IU of Vitamin D for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enteral Vitamin D3 100,000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm where subjects receive 100,000 IU of Vitamin D for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive Substance</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm where patients receive inactive substance for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteral Vitamin D3 50,000 IU</intervention_name>
    <description>Enteral Vitamin D3 50,000IU x 5 days (total dose 250,000IU)</description>
    <arm_group_label>Enteral vitamin D3 50,000 IU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteral Vitamin D3 100,000IU</intervention_name>
    <description>Enteral Vitamin D3 100,000IU over 5 days (total 500,000IU)</description>
    <arm_group_label>Enteral Vitamin D3 100,000 IU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inactive substance</intervention_name>
    <description>Inactive substance given enterally for 5 days.</description>
    <arm_group_label>Inactive Substance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Receiving care in an intensive care unit (ICU)

          -  Age greater than 18 years

          -  Expected to require mechanical ventilation for at least 72 hours after entry

          -  Expected to survive and remain in the ICU for at least 96 hours after study entry

          -  To enable delivery of study drug, the subject has enteral access in place and is
             deemed able to tolerate enteral drug administration

        Exclusion Criteria:

          -  Inability to obtain or declined informed consent from the subject and/or legally
             authorized representative

          -  Pregnancy

          -  Ongoing shock

          -  Current hypercalcemia (albumin-corrected serum calcium &gt; 10.8 mg/dL or ionized calcium
             &gt; 5.2 mg/dL)

          -  History of therapy with high-dose vitamin D to treat vitamin D deficiency within
             previous 6 months

          -  History of disorders associated with hypercalcemia; history of cancer with history of
             hypercalcemia within the past 1 year, hyperparathyroidism, sarcoidosis,
             nephrolithiasis]

          -  Chronic renal dysfunction requiring chronic dialysis

          -  Known history of cirrhosis

          -  History of AIDS

          -  The patient has received any investigational drug within 60 days prior to study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Martin, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Ziegler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tejada Artigas A, Bello Dronda S, Chacón Vallés E, Muñoz Marco J, Villuendas Usón MC, Figueras P, Suarez FJ, Hernández A. Risk factors for nosocomial pneumonia in critically ill trauma patients. Crit Care Med. 2001 Feb;29(2):304-9.</citation>
    <PMID>11246310</PMID>
  </reference>
  <reference>
    <citation>Winther B, Greve JM, Gwaltney JM Jr, Innes DJ, Eastham JR, McClelland A, Hendley JO. Surface expression of intercellular adhesion molecule 1 on epithelial cells in the human adenoid. J Infect Dis. 1997 Aug;176(2):523-5.</citation>
    <PMID>9237723</PMID>
  </reference>
  <reference>
    <citation>Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr. 2010 May;91(5):1255-60. doi: 10.3945/ajcn.2009.29094. Epub 2010 Mar 10.</citation>
    <PMID>20219962</PMID>
  </reference>
  <reference>
    <citation>Manaseki-Holland S, Qader G, Isaq Masher M, Bruce J, Zulf Mughal M, Chandramohan D, Walraven G. Effects of vitamin D supplementation to children diagnosed with pneumonia in Kabul: a randomised controlled trial. Trop Med Int Health. 2010 Oct;15(10):1148-55. doi: 10.1111/j.1365-3156.2010.02578.x. Epub 2010 Aug 17.</citation>
    <PMID>20723187</PMID>
  </reference>
  <reference>
    <citation>Yim S, Dhawan P, Ragunath C, Christakos S, Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3). J Cyst Fibros. 2007 Nov 30;6(6):403-10. Epub 2007 Apr 27.</citation>
    <PMID>17467345</PMID>
  </reference>
  <reference>
    <citation>De Smet K, Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett. 2005 Sep;27(18):1337-47. Review.</citation>
    <PMID>16215847</PMID>
  </reference>
  <reference>
    <citation>Barlow PG, Beaumont PE, Cosseau C, Mackellar A, Wilkinson TS, Hancock RE, Haslett C, Govan JR, Simpson AJ, Davidson DJ. The human cathelicidin LL-37 preferentially promotes apoptosis of infected airway epithelium. Am J Respir Cell Mol Biol. 2010 Dec;43(6):692-702. doi: 10.1165/rcmb.2009-0250OC. Epub 2010 Jan 22.</citation>
    <PMID>20097832</PMID>
  </reference>
  <reference>
    <citation>Jeng L, Yamshchikov AV, Judd SE, Blumberg HM, Martin GS, Ziegler TR, Tangpricha V. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med. 2009 Apr 23;7:28. doi: 10.1186/1479-5876-7-28.</citation>
    <PMID>19389235</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2011</study_first_submitted>
  <study_first_submitted_qc>June 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2011</study_first_posted>
  <results_first_submitted>July 28, 2016</results_first_submitted>
  <results_first_submitted_qc>November 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2017</results_first_posted>
  <last_update_submitted>November 10, 2016</last_update_submitted>
  <last_update_submitted_qc>November 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Greg S. Martin, M.D., M.Sc.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>critical care</keyword>
  <keyword>nosocomial infection</keyword>
  <keyword>antiAntimicrobial peptide expression</keyword>
  <keyword>LL-37</keyword>
  <keyword>hBD-2</keyword>
  <keyword>cathelicidin</keyword>
  <keyword>microbial peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were recruited from critical care units at three hospitals in Atlanta, Georgia. 658 patients were assessed for eligibility, of these 562 did not meet inclusion and exclusion criteria. 65 eligible patients declined to participate while 31 gave informed consent and were randomized to one of the three study arms.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
        </group>
        <group group_id="P2">
          <title>250,000 IU of Vitamin D3</title>
          <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
        </group>
        <group group_id="P3">
          <title>500,000 IU of Vitamin D3</title>
          <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11">One participant was transferred to comfort care prior to completing the intervention.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10">The transferred participant was included in the intent to treat analyses.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Spouse withdrew participant from study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The participant randomized to the 250,000 IU of Vitamin D3 study arm, whose spouse withdrew consent to participate in the study, is not represented in the Baseline Analysis Population.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
        </group>
        <group group_id="B2">
          <title>250,000 IU of Vitamin D3</title>
          <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
        </group>
        <group group_id="B3">
          <title>500,000 IU of Vitamin D3</title>
          <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/Alaskan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vitamin D at baseline</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Deficient (&lt;20 ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insufficient (20-30 ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sufficient (&gt;30 ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary Artery Disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Coronary Artery Disease Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Coronary Artery Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Congestive Heart Failure</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Congestive Heart Failure Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Congestive Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diabetes Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic Obstructive Pulmonary Disease (COPD)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>COPD Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No COPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asthma Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Baseline</title>
        <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the baseline measurement.</description>
        <time_frame>Baseline</time_frame>
        <population>Blood samples were obtained every 7 days while participants remained hospitalized. Follow up discontinued once the participant was discharged from the hospital. At the baseline time point, 10 patients were randomized to the placebo arm, 9 to the arm receiving 250,000 IU of Vitamin D3, and 11 to the arm receiving 500,000 of Vitamin D3.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
          </group>
          <group group_id="O2">
            <title>250,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
          </group>
          <group group_id="O3">
            <title>500,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Baseline</title>
          <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the baseline measurement.</description>
          <population>Blood samples were obtained every 7 days while participants remained hospitalized. Follow up discontinued once the participant was discharged from the hospital. At the baseline time point, 10 patients were randomized to the placebo arm, 9 to the arm receiving 250,000 IU of Vitamin D3, and 11 to the arm receiving 500,000 of Vitamin D3.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Day 7</title>
        <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the Day 7 measurement.</description>
        <time_frame>Day 7</time_frame>
        <population>Blood samples were obtained every 7 days while participants remained hospitalized. Follow up discontinued once the participant was discharged from the hospital. The number of participants analyzed at each time point decreased over the course of the study as participants were discharged from the hospital.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
          </group>
          <group group_id="O2">
            <title>250,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
          </group>
          <group group_id="O3">
            <title>500,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Day 7</title>
          <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the Day 7 measurement.</description>
          <population>Blood samples were obtained every 7 days while participants remained hospitalized. Follow up discontinued once the participant was discharged from the hospital. The number of participants analyzed at each time point decreased over the course of the study as participants were discharged from the hospital.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Day 14</title>
        <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the Day 14 measurement.</description>
        <time_frame>Day 14</time_frame>
        <population>Blood samples were obtained every 7 days while participants remained hospitalized. Follow up discontinued once the participant was discharged from the hospital. The number of participants analyzed for each time point decreased over the course of the study as participants were discharged from the hospital.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
          </group>
          <group group_id="O2">
            <title>250,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
          </group>
          <group group_id="O3">
            <title>500,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Day 14</title>
          <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the Day 14 measurement.</description>
          <population>Blood samples were obtained every 7 days while participants remained hospitalized. Follow up discontinued once the participant was discharged from the hospital. The number of participants analyzed for each time point decreased over the course of the study as participants were discharged from the hospital.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Day 21</title>
        <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the Day 21 measurement.</description>
        <time_frame>Day 21</time_frame>
        <population>Blood samples were obtained every 7 days while participants remained hospitalized. Follow up discontinued once the participant was discharged from the hospital. The number of participants analyzed at each time point decreased over the course of the study as participants were discharged from the hospital.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
          </group>
          <group group_id="O2">
            <title>250,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
          </group>
          <group group_id="O3">
            <title>500,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Day 21</title>
          <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the Day 21 measurement.</description>
          <population>Blood samples were obtained every 7 days while participants remained hospitalized. Follow up discontinued once the participant was discharged from the hospital. The number of participants analyzed at each time point decreased over the course of the study as participants were discharged from the hospital.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Day 28</title>
        <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the Day 28 measurement.</description>
        <time_frame>Day 28</time_frame>
        <population>Blood samples were obtained every 7 days while participants remained hospitalized. Follow up discontinued once the participant was discharged from the hospital. The number of participants analyzed at each time point decreased over the course of the study as participants were discharged from the hospital.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
          </group>
          <group group_id="O2">
            <title>250,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
          </group>
          <group group_id="O3">
            <title>500,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Day 28</title>
          <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the Day 28 measurement.</description>
          <population>Blood samples were obtained every 7 days while participants remained hospitalized. Follow up discontinued once the participant was discharged from the hospital. The number of participants analyzed at each time point decreased over the course of the study as participants were discharged from the hospital.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Day 84</title>
        <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the Day 84 measurement.</description>
        <time_frame>Day 84</time_frame>
        <population>Blood samples were obtained every 7 days while participants remained hospitalized. Follow up discontinued once the participant was discharged from the hospital. The number of participants analyzed at each time point decreased over the course of the study as participants were discharged from the hospital.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
          </group>
          <group group_id="O2">
            <title>250,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
          </group>
          <group group_id="O3">
            <title>500,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Plasma 25(OH)D Concentration &gt;30ng/mL at Day 84</title>
          <description>The number of participants with a plasma 25(OH)D concentration in the desirable range (defined as greater than 30 ng/mL) at the Day 84 measurement.</description>
          <population>Blood samples were obtained every 7 days while participants remained hospitalized. Follow up discontinued once the participant was discharged from the hospital. The number of participants analyzed at each time point decreased over the course of the study as participants were discharged from the hospital.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma LL-37 Levels</title>
        <description>Plasma LL-37 was measured at Baseline, Day 7 and Day 14.</description>
        <time_frame>Baseline, Day 7, Day 14</time_frame>
        <population>For the Day 14 analysis there were 8 participants in the Placebo arm, 6 participants in the 250,000 of Vitamin D arm, and 5 participants in the 500,000 of Vitamin D arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
          </group>
          <group group_id="O2">
            <title>250,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
          </group>
          <group group_id="O3">
            <title>500,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma LL-37 Levels</title>
          <description>Plasma LL-37 was measured at Baseline, Day 7 and Day 14.</description>
          <population>For the Day 14 analysis there were 8 participants in the Placebo arm, 6 participants in the 250,000 of Vitamin D arm, and 5 participants in the 500,000 of Vitamin D arm.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7 Compared to Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" lower_limit="-18.9" upper_limit="26.9"/>
                    <measurement group_id="O2" value="6.0" lower_limit="-13.4" upper_limit="39.2"/>
                    <measurement group_id="O3" value="-13.5" lower_limit="-48.4" upper_limit="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 Compared to Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="-24.6" upper_limit="10.8"/>
                    <measurement group_id="O2" value="-12.3" lower_limit="-36.1" upper_limit="8.1"/>
                    <measurement group_id="O3" value="-6.0" lower_limit="-27.3" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Time on Ventilator</title>
        <description>The number of days spent on mechanical ventilation was collected for all study participants and the average number of days for each study arm is reported.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
          </group>
          <group group_id="O2">
            <title>250,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
          </group>
          <group group_id="O3">
            <title>500,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Time on Ventilator</title>
          <description>The number of days spent on mechanical ventilation was collected for all study participants and the average number of days for each study arm is reported.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="15"/>
                    <measurement group_id="O2" value="12" spread="10"/>
                    <measurement group_id="O3" value="14" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Time in Intensive Care Unit (ICU)</title>
        <description>The number of days spent in the intensive care unit (ICU) was collected for each participant and the average number of days for each study arm is reported.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
          </group>
          <group group_id="O2">
            <title>250,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
          </group>
          <group group_id="O3">
            <title>500,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Time in Intensive Care Unit (ICU)</title>
          <description>The number of days spent in the intensive care unit (ICU) was collected for each participant and the average number of days for each study arm is reported.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="14"/>
                    <measurement group_id="O2" value="17" spread="14"/>
                    <measurement group_id="O3" value="15" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Time in Hospital</title>
        <description>The number of days that each participant spent in the hospital was collected and the average number of days for each study arm is reported.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
          </group>
          <group group_id="O2">
            <title>250,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
          </group>
          <group group_id="O3">
            <title>500,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Time in Hospital</title>
          <description>The number of days that each participant spent in the hospital was collected and the average number of days for each study arm is reported.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="19"/>
                    <measurement group_id="O2" value="25" spread="14"/>
                    <measurement group_id="O3" value="18" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sequential Organ Failure Assessment (SOFA) Score</title>
        <description>Change in Sequential Organ Failure Assessment (SOFA) score between Baseline and Day 7. The Sequential Organ Failure Assessment (SOFA) score is a mortality prediction score that is based on the degree of dysfunction of 6 organ systems (respiratory, nervous, cardiovascular, liver, coagulation, and kidneys). A score ranges from 0-24. 0 (normal) to 4 (high degree of dysfunction) is given for each organ system, with a higher score indicating greater severity. A score of 0-6 is associated with a mortality rate of less than 10% while a score between 16 and 24 is associated with a greater than 90% mortality rate. Scores decreasing between the Baseline and Day 7 measurements are represented as negative values for the change in SOFA score.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>SOFA score obtained daily while in the ICU. The portion of the study participants included in the analysis of the change in SOFA score between Baseline and Day 7 is limited to participants having values for both time points..</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
          </group>
          <group group_id="O2">
            <title>250,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
          </group>
          <group group_id="O3">
            <title>500,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sequential Organ Failure Assessment (SOFA) Score</title>
          <description>Change in Sequential Organ Failure Assessment (SOFA) score between Baseline and Day 7. The Sequential Organ Failure Assessment (SOFA) score is a mortality prediction score that is based on the degree of dysfunction of 6 organ systems (respiratory, nervous, cardiovascular, liver, coagulation, and kidneys). A score ranges from 0-24. 0 (normal) to 4 (high degree of dysfunction) is given for each organ system, with a higher score indicating greater severity. A score of 0-6 is associated with a mortality rate of less than 10% while a score between 16 and 24 is associated with a greater than 90% mortality rate. Scores decreasing between the Baseline and Day 7 measurements are represented as negative values for the change in SOFA score.</description>
          <population>SOFA score obtained daily while in the ICU. The portion of the study participants included in the analysis of the change in SOFA score between Baseline and Day 7 is limited to participants having values for both time points..</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="3"/>
                    <measurement group_id="O2" value="-3" spread="3"/>
                    <measurement group_id="O3" value="-2" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospital Acquired Infections</title>
        <description>The number of study participants who had a hospital acquired infection.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
          </group>
          <group group_id="O2">
            <title>250,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
          </group>
          <group group_id="O3">
            <title>500,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospital Acquired Infections</title>
          <description>The number of study participants who had a hospital acquired infection.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospital Mortality Cases</title>
        <description>The number of study participants who died while in the hospital was collected.</description>
        <time_frame>12 weeks</time_frame>
        <population>The number of participants in the hospital mortality analysis for the arm receiving 500,000 IU of Vitamin D3 was 10, rather than 11.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
          </group>
          <group group_id="O2">
            <title>250,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
          </group>
          <group group_id="O3">
            <title>500,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospital Mortality Cases</title>
          <description>The number of study participants who died while in the hospital was collected.</description>
          <population>The number of participants in the hospital mortality analysis for the arm receiving 500,000 IU of Vitamin D3 was 10, rather than 11.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 84 Mortality</title>
        <description>The number of participants who died prior to the end of the study (Day 84) was collected.</description>
        <time_frame>Day 84</time_frame>
        <population>The number of participants in the hospital mortality analysis for the arm receiving 500,000 IU of Vitamin D3 was 10, rather than 11, as one participant withdrew.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
          </group>
          <group group_id="O2">
            <title>250,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally</description>
          </group>
          <group group_id="O3">
            <title>500,000 IU of Vitamin D3</title>
            <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally</description>
          </group>
        </group_list>
        <measure>
          <title>Day 84 Mortality</title>
          <description>The number of participants who died prior to the end of the study (Day 84) was collected.</description>
          <population>The number of participants in the hospital mortality analysis for the arm receiving 500,000 IU of Vitamin D3 was 10, rather than 11, as one participant withdrew.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data regarding serious adverse events and non-serious adverse events were collected from the start of treatment until 30 days after study drug discontinuation (35 days in total). Ongoing events were monitored until resolution.</time_frame>
      <desc>As critically ill study patients are known to have a high morbidity and mortality rate, no adverse events specifically due to the study drug were expected. The clinical course of every participant was monitored to record any unexpected adverse events and all serious adverse events (SAEs). SAEs were defined as death, rehospitalization or reoperation within 30 days, cardiopulmonary arrest, pulmonary aspiration during feeding tube administration, new cancer diagnosis, and congenital anomalies.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants randomized to receive an inactive substance administered enterally for 5 days</description>
        </group>
        <group group_id="E2">
          <title>250,000 IU of Vitamin D3</title>
          <description>Participants randomized to receive 50,000 IU of Vitamin D3 per day for 5 days, for a total dose of 250,000 IU administered enterally.</description>
        </group>
        <group group_id="E3">
          <title>500,000 IU of Vitamin D3</title>
          <description>Participants randomized to receive 100,000 IU per day of Vitamin D3 for 5 days, for a total dose of 500,000 administered enterally.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <description>Cardiopulmonary arrest</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Re-hospitalization</sub_title>
                <description>Re-hospitalization within 30 days of study drug discontinuation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Death within 30 days of study drug discontinuation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations to generalizability of this pilot study include the small sample size and imbalances in chronic conditions between treatment arms at study entry.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jenny Han, MD</name_or_title>
      <organization>Emory University</organization>
      <phone>404-616-0821</phone>
      <email>jehan2@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

